PMID: 8949736Sep 21, 1996Paper

Adjuvant treatment of colonic cancers

La Presse médicale
G FreyerJ P Gérard

Abstract

In the last decade, adjuvant chemotherapy has led to significant improvement in survival for large bowel cancer patients. The association of 5-FU plus levamisole was the first described and demonstrated its efficacy in stage Dukes C (T1,2,3,4 N1 M0) completely-resected adenocarcinoma. Recently, chemotherapy with 5-FU and folinic acid was recommended on the basis of randomized trials. Advances in adjuvant chemotherapy may result in increasing 5-FU doses as described in metastatic colorectal carcinomas, and in use of new drugs such as oxaliplatin or raltitrexed, whose activity has been well-studied in Dukes D (M1) carcinomas. Immunotherapy, intraperitoneal and intraportal infusion of chemotherapy are promising approaches but still in evaluation. The main difficulty for the future is to define the best therapeutic regimen in order to reach the highest improvement in survival.

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.